Selenite is a potent cytotoxic agent for human primary AML cells

Cancer Letters

Volumn 282, Issue 1, 2009, Pages 116-123

  Olm, Eric ^a   Jönsson Videsäter, Kerstin ^a   Ribera Cortada, Inmaculada ^a   Fernandes, Aristi P ^a   Eriksson, Lennart C ^a   Lehmann, Sören ^a   Rundlöf, Anna Klara ^a   Paul, Christer ^a   Björnstedt, Mikael ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer therapy; Drug resistance; Selenium compounds

Indexed keywords

AMSACRINE; CLADRIBINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; IDARUBICIN; MESSENGER RNA; MITOXANTRONE; SELENITE; THIOREDOXIN REDUCTASE 1;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; EX VIVO STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ADENOSINE TRIPHOSPHATE; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CELL SURVIVAL; CYTOTOXINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; SODIUM SELENITE;

EID: 67649406058     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.03.010     Document Type: Article

References (51)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics. CA Cancer J. Clin. 57 (2007) 43-66
2. Institute NC. Surveillance, Epidemiology, and End-results. 2004.
3. Burnett A.K., and Mohite U. Treatment of older patients with acute myeloid leukemia - new agents. Semin. Hematol. 43 (2006) 96-106
4. Leith C.P., Kopecky K.J., Godwin J., McConnell T., Slovak M.L., Chen I.M., et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A southwest oncology group study. Blood 89 (1997) 3323-3329
5. Rayman M.P. The importance of selenium to human health. Lancet 356 (2000) 233-241
6. Yu S.Y., Zhu Y.J., and Li W.G. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol. Trace Elem. Res. 56 (1997) 117-124
7. Clark L.C., Combs Jr. G.F., Turnbull B.W., Slate E.H., Chalker D.K., Chow J., et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional prevention of cancer study group. Jama 276 (1996) 1957-1963
8. Lipinski B. Rationale for the treatment of cancer with sodium selenite. Med. Hypotheses 64 (2005) 806-810
9. Papp L.V., Lu J., Holmgren A., and Khanna K.K. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid. Redox Signal 9 (2007) 775-806
10. Björkhem-Bergman L., Jönsson K., Eriksson L.C., Olsson J.M., Lehmann S., Paul C., et al. Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity. Effects on thioredoxin reductase and glutathione reductase. Biochem. Pharmacol. 63 (2002) 1875-1884
11. Bandura L., Drukala J., Wolnicka-Glubisz A., Björnstedt M., and Korohoda W. Differential effects of selenite and selenate on human melanocytes, keratinocytes, and melanoma cells. Biochem. Cell Biol. 83 (2005) 196-211
12. Snyder R.D. Effects of sodium selenite on DNA and carcinogen-induced DNA repair in human diploid fibroblasts. Cancer Lett. 34 (1987) 73-81
13. Nilsonne G., Sun X., Nyström C., Rundlöf A.K., Potamitou Fernandes A., Björnstedt M., et al. Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress. Free Radic. Biol. Med. 41 (2006) 874-885
14. Husbeck B., Nonn L., Peehl D.M., and Knox S.J. Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate 66 (2006) 218-225
15. Jönsson-Videsäter K., Björkhem-Bergman L., Hossain A., Söderberg A., Eriksson L.C., Paul C., et al. Selenite-induced apoptosis in doxorubicin-resistant cells and effects on the thioredoxin system. Biochem. Pharmacol. 67 (2004) 513-522
16. Zhao R., Xiang N., Domann F.E., and Zhong W. Expression of p53 enhances selenite-induced superoxide production and apoptosis in human prostate cancer cells. Cancer Res. 66 (2006) 2296-2304
17. Zuo L., Li J., Yang Y., Wang X., Shen T., Xu C.M., et al. Sodium selenite induces apoptosis in acute promyelocytic leukemia-derived NB4 cells by a caspase-3-dependent mechanism and a redox pathway different from that of arsenic trioxide. Ann. Hematol. 83 (2004) 751-758
18. Li J., Zuo L., Shen T., Xu C.M., and Zhang Z.N. Induction of apoptosis by sodium selenite in human acute promyelocytic leukemia NB4 cells: involvement of oxidative stress and mitochondria. J. Trace Elem. Med. Biol. 17 (2003) 19-26
19. Holmgren A. Bovine thioredoxin system. Purification of thioredoxin reductase from calf liver and thymus and studies of its function in disulfide reduction. J. Biol. Chem. 252 (1977) 4600-4606
20. Björnstedt M., Kumar S., Björkhem L., Spyrou G., and Holmgren A. Selenium and the thioredoxin and glutaredoxin systems. Biomed. Environ. Sci. 10 (1997) 271-279
21. Arnér E.S., and Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267 (2000) 6102-6109
22. Gromer S., Urig S., and Becker K. The thioredoxin system - from science to clinic. Med. Res. Rev. 24 (2004) 40-89
23. Zhong L., and Holmgren A. Essential role of selenium in the catalytic activities of mammalian thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations. J. Biol. Chem. 275 (2000) 18121-18128
24. Lee S.R., Kim J.R., Kwon K.S., Yoon H.W., Levine R.L., Ginsburg A., et al. Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver. J. Biol. Chem. 274 (1999) 4722-4734
25. Miranda-Vizuete A., Damdimopoulos A.E., Pedrajas J.R., Gustafsson J.A., and Spyrou G. Human mitochondrial thioredoxin reductase cDNA cloning, expression and genomic organization. Eur. J. Biochem. 261 (1999) 405-412
26. Sun Q.A., Kirnarsky L., Sherman S., and Gladyshev V.N. Selenoprotein oxidoreductase with specificity for thioredoxin and glutathione systems. Proc. Natl. Acad. Sci. USA 98 (2001) 3673-3678
27. Rundlöf A.K., and Arnér E.S. Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. Antioxid. Redox Signal 6 (2004) 41-52
28. Rundlöf A.K., Janard M., Miranda-Vizuete A., and Arnér E.S. Evidence for intriguingly complex transcription of human thioredoxin reductase 1. Free Radic. Biol. Med. 36 (2004) 641-656
29. Damdimopoulos A.E., Miranda-Vizuete A., Treuter E., Gustafsson J.A., and Spyrou G. An alternative splicing variant of the selenoprotein thioredoxin reductase is a modulator of estrogen signaling. J. Biol. Chem. 279 (2004) 38721-38729
30. Su D., and Gladyshev V.N. Alternative splicing involving the thioredoxin reductase module in mammals: a glutaredoxin-containing thioredoxin reductase 1. Biochemistry 43 (2004) 12177-12188
31. Rundlöf A.K., Fernandes A.P., Selenius M., Babic M., Shariatgorji M., Nilsonne G., et al. Quantification of alternative mRNA species and identification of thioredoxin reductase 1 isoforms in human tumor cells. Differentiation 75 (2007) 123-132
32. Kumar S., Björnstedt M., and Holmgren A. Selenite is a substrate for calf thymus thioredoxin reductase and thioredoxin and elicits a large non-stoichiometric oxidation of NADPH in the presence of oxygen. Eur. J. Biochem. 207 (1992) 435-439
33. Björnstedt M., Kumar S., and Holmgren A. Selenodiglutathione is a highly efficient oxidant of reduced thioredoxin and a substrate for mammalian thioredoxin reductase. J. Biol. Chem. 267 (1992) 8030-8034
34. Nguyen P., Awwad R.T., Smart D.D., Spitz D.R., and Gius D. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett. (2005)
35. Urig S., and Becker K. On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin. Cancer Biol. 16 (2006) 452-465
36. Sundman-Engberg B., Tidefelt U., Liliemark J., and Paul C. Intracellular concentrations of anti cancer drugs in leukemic cells in vitro vs. in vivo. Cancer Chemother. Pharmacol. 25 (1990) 252-256
37. Kangas L., Gronroos M., and Nieminen A.L. Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med. Biol. 62 (1984) 338-343
38. Andreotti P.E., Cree I.A., Kurbacher C.M., Hartmann D.M., Linder D., Harel G., et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res. 55 (1995) 5276-5282
39. Caffrey P.B., and Frenkel G.D. Treatment of human ovarian tumor xenografts with selenite prevents the melphalan-induced development of drug resistance. Anticancer Res. 18 (1998) 3017-3020
40. Frenkel G.D., and Caffrey P.B. A prevention strategy for circumventing drug resistance in cancer chemotherapy. Curr. Pharm. Des. 7 (2001) 1595-1614
41. Zhao R., Domann F.E., and Zhong W. Apoptosis induced by selenomethionine and methioninase is superoxide mediated and p53 dependent in human prostate cancer cells. Mol. Cancer Ther. 5 (2006) 3275-3284
42. Fernandes A.P., and Holmgren A. Glutaredoxins: glutathione-dependent redox enzymes with functions far beyond a simple thioredoxin backup system. Antioxid. Redox Signal 6 (2004) 63-74
43. Enoksson M., Fernandes A.P., Prast S., Lillig C.H., Holmgren A., and Orrenius S. Overexpression of glutaredoxin 2 attenuates apoptosis by preventing cytochrome c release. Biochem. Biophys. Res. Commun. 327 (2005) 774-779
44. Pan S., and Berk B.C. Glutathiolation regulates tumor necrosis factor-alpha-induced caspase-3 cleavage and apoptosis: key role for glutaredoxin in the death pathway. Circ. Res. 100 (2007) 213-219
45. Spyrou G., Björnstedt M., Skog S., and Holmgren A. Selenite and selenate inhibit human lymphocyte growth via different mechanisms. Cancer Res. 56 (1996) 4407-4412
46. Berggren M., Gallegos A., Gasdaska J., and Powis G. Cellular thioredoxin reductase activity is regulated by selenium. Anticancer Res. 17 (1997) 3377-3380
47. Papp L.V., Lu J., Striebel F., Kennedy D., Holmgren A., and Khanna K.K. The redox state of SECIS binding protein 2 controls its localization and selenocysteine incorporation function. Mol. Cell Biol. 26 (2006) 4895-4910
48. Björkhem-Bergman L., Torndal U.B., Eken S., Nystrom C., Capitanio A., Larsen E.H., et al. Selenium prevents tumor development in a rat model for chemical carcinogenesis. Carcinogenesis 26 (2005) 125-131
49. Whanger P., Vendeland S., Park Y.C., and Xia Y. Metabolism of subtoxic levels of selenium in animals and humans. Ann. Clin. Lab Sci. 26 (1996) 99-113
50. Yang G., Zhou R., Yin S., Gu L., Yan B., Liu Y., et al. Studies of safe maximal daily dietary selenium intake in a seleniferous area in China. I. Selenium intake and tissue selenium levels of the inhabitants. J. Trace Elem. Electrolytes Health Dis. 3 (1989) 77-87
51. Weisberger A.S., and Suhrland L.G. Studies on analogues of L-cysteine and L-cystine. III. The effect of selenium cystine on leukemia. Blood 11 (1956) 19-30